Skip to main content
Top
Published in: BMC Infectious Diseases 1/2010

Open Access 01-12-2010 | Research article

Clinical features and predictors of mortality in admitted patients with community- and hospital-acquired legionellosis: A Danish historical cohort study

Authors: Sanne Jespersen, Ole S Søgaard, Henrik C Schønheyder, Michael J Fine, Lars Østergaard

Published in: BMC Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Background

Legionella is a common cause of bacterial pneumonia. Community-acquired [CAL] and hospital-acquired legionellosis [HAL] may have different presentations and outcome. We aimed to compare clinical characteristics and examine predictors of mortality for CAL and HAL.

Methods

We identified hospitalized cases of legionellosis in 4 Danish counties from January 1995 to December 2005 using the Danish national surveillance system and databases at departments of clinical microbiology. Clinical and laboratory data were retrieved from medical records; vital status was obtained from the Danish Civil Registration System. We calculated 30- and 90-day case fatality rates and identified independent predictors of mortality using logistic regression analyses.

Results

We included 272 cases of CAL and 60 cases of HAL. Signs and symptoms of HAL were less pronounced than for CAL and time from in-hospital symptoms to legionellosis diagnosis was shorter for CAL than for HAL (5.5 days vs. 12 days p < 0.001). Thirty-day case fatality was 12.9% for CAL and 33.3% for HAL; similarly 90-day case fatalities in the two groups were 15.8% and 55.0%, respectively. In a logistic regression analysis (excluding symptoms and laboratory tests) age >65 years (OR = 2.6, 95% CI: 1.1-5.9) and Charlson comorbidty index ≥2 (OR = 2.7, 95% CI: 1.1-6.5) were associated with an increased risk of death in CAL. We identified no statistically significant predictors of 30-day mortality in HAL.

Conclusions

Signs and symptoms were less pronounced in HAL compared to CAL. Conversely, 30-day case fatality was almost 3 times higher. Clinical awareness is important for the timely diagnosis and treatment especially of HAL. There is a need for further studies of prognostic factors in order to improve the therapeutic approach to legionellosis and potentially reduce mortality.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fields BS, Benson RF, Besser RE: Legionella and Legionnaires' disease: 25 years of investigation. Clin Microbiol Rev. 2002, 15 (3): 506-26. 10.1128/CMR.15.3.506-526.2002.CrossRefPubMedPubMedCentral Fields BS, Benson RF, Besser RE: Legionella and Legionnaires' disease: 25 years of investigation. Clin Microbiol Rev. 2002, 15 (3): 506-26. 10.1128/CMR.15.3.506-526.2002.CrossRefPubMedPubMedCentral
2.
go back to reference Neil K, Berkelman R: Increasing incidence of legionellosis in the United States, 1990-2005: changing epidemiologic trends. Clin Infect Dis. 2008, 47 (5): 591-9. 10.1086/590557.CrossRefPubMed Neil K, Berkelman R: Increasing incidence of legionellosis in the United States, 1990-2005: changing epidemiologic trends. Clin Infect Dis. 2008, 47 (5): 591-9. 10.1086/590557.CrossRefPubMed
3.
go back to reference Dedicoat M, Venkatesan P: The treatment of Legionnaires' disease. J Antimicrob Chemother. 1999, 43 (6): 747-52. 10.1093/jac/43.6.747.CrossRefPubMed Dedicoat M, Venkatesan P: The treatment of Legionnaires' disease. J Antimicrob Chemother. 1999, 43 (6): 747-52. 10.1093/jac/43.6.747.CrossRefPubMed
4.
go back to reference Vergis EN, Indorf A, File TM, et al: Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med. 2000, 160 (9): 1294-300. 10.1001/archinte.160.9.1294.CrossRefPubMed Vergis EN, Indorf A, File TM, et al: Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med. 2000, 160 (9): 1294-300. 10.1001/archinte.160.9.1294.CrossRefPubMed
5.
go back to reference Dournon E, Mayaud C, Wolff M, et al: Comparison of the activity of three antibiotic regimens in severe Legionnaires' disease. J Antimicrob Chemother. 1990, 26 (Suppl B): 129-39.CrossRefPubMed Dournon E, Mayaud C, Wolff M, et al: Comparison of the activity of three antibiotic regimens in severe Legionnaires' disease. J Antimicrob Chemother. 1990, 26 (Suppl B): 129-39.CrossRefPubMed
6.
go back to reference Cunha BA: Clinical features of legionnaires' disease. Semin Respir Infect. 1998, 13 (2): 116-27.PubMed Cunha BA: Clinical features of legionnaires' disease. Semin Respir Infect. 1998, 13 (2): 116-27.PubMed
7.
go back to reference Strampfer MJ, Cunha BA: Clinical and laboratory aspects of Legionnaire's disease. Smin Respir Infect. 1987, 2 (4): 228-34. Strampfer MJ, Cunha BA: Clinical and laboratory aspects of Legionnaire's disease. Smin Respir Infect. 1987, 2 (4): 228-34.
8.
go back to reference Sopena N, Sabria-Leal M, Pedro-Botet ML, et al: Comparative study of the clinical presentation of Legionella pneumonia and other community-acquired pneumonias. Chest. 1998, 113 (5): 1195-200. 10.1378/chest.113.5.1195.CrossRefPubMed Sopena N, Sabria-Leal M, Pedro-Botet ML, et al: Comparative study of the clinical presentation of Legionella pneumonia and other community-acquired pneumonias. Chest. 1998, 113 (5): 1195-200. 10.1378/chest.113.5.1195.CrossRefPubMed
9.
go back to reference Heath CH, Grove DI, Looke DF: Delay in appropriate therapy of Legionella pneumonia associated with increased mortality. Eur J Clin Microbiol Infect Dis. 1996, 15 (4): 286-90. 10.1007/BF01695659.CrossRefPubMed Heath CH, Grove DI, Looke DF: Delay in appropriate therapy of Legionella pneumonia associated with increased mortality. Eur J Clin Microbiol Infect Dis. 1996, 15 (4): 286-90. 10.1007/BF01695659.CrossRefPubMed
10.
go back to reference Gacouin A, Le Tulzo Y, Lavoue S, et al: Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy. Intensive Care Med. 2002, 28 (6): 686-91. 10.1007/s00134-002-1304-8.CrossRefPubMed Gacouin A, Le Tulzo Y, Lavoue S, et al: Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy. Intensive Care Med. 2002, 28 (6): 686-91. 10.1007/s00134-002-1304-8.CrossRefPubMed
11.
go back to reference el-Ebiary M, Sarmiento X, Torres A, et al: Prognostic factors of severe Legionella pneumonia requiring admission to ICU. Am J Respir Crit Care Med. 1997, 156 (5): 1467-72.CrossRefPubMed el-Ebiary M, Sarmiento X, Torres A, et al: Prognostic factors of severe Legionella pneumonia requiring admission to ICU. Am J Respir Crit Care Med. 1997, 156 (5): 1467-72.CrossRefPubMed
13.
go back to reference Jespersen S, Sogaard OS, Fine MJ, Ostergaard L: The relationship between diagnostic tests and case characteristics in Legionnaires' disease. Scand J Infect Dis. 2009, 8: 1-8. Jespersen S, Sogaard OS, Fine MJ, Ostergaard L: The relationship between diagnostic tests and case characteristics in Legionnaires' disease. Scand J Infect Dis. 2009, 8: 1-8.
14.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40 (5): 373-83. 10.1016/0021-9681(87)90171-8.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40 (5): 373-83. 10.1016/0021-9681(87)90171-8.CrossRefPubMed
15.
go back to reference de Groot V, Beckerman H, Lankhorst GJ, Bouter LM: How to measure comorbidity. a critical review of available methods. J Clin Epidemiol. 2003, 56 (3): 221-9. 10.1016/S0895-4356(02)00585-1.CrossRefPubMed de Groot V, Beckerman H, Lankhorst GJ, Bouter LM: How to measure comorbidity. a critical review of available methods. J Clin Epidemiol. 2003, 56 (3): 221-9. 10.1016/S0895-4356(02)00585-1.CrossRefPubMed
16.
go back to reference Lim WS, Eerden van der MM, Laing R, et al: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003, 58 (5): 377-82. 10.1136/thorax.58.5.377.CrossRefPubMedPubMedCentral Lim WS, Eerden van der MM, Laing R, et al: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003, 58 (5): 377-82. 10.1136/thorax.58.5.377.CrossRefPubMedPubMedCentral
17.
go back to reference Fine MJ, Auble TE, Yealy DM, et al: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997, 336 (4): 243-50. 10.1056/NEJM199701233360402.CrossRefPubMed Fine MJ, Auble TE, Yealy DM, et al: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997, 336 (4): 243-50. 10.1056/NEJM199701233360402.CrossRefPubMed
18.
go back to reference Helms CM, Viner JP, Weisenburger DD, Chiu LC, Renner ED, Johnson W: Sporadic Legionnaires' disease: clinical observations on 87 nosocomial and community-acquired cases. Am J Med Sci. 1984, 288 (1): 2-12. 10.1097/00000441-198407000-00001.CrossRefPubMed Helms CM, Viner JP, Weisenburger DD, Chiu LC, Renner ED, Johnson W: Sporadic Legionnaires' disease: clinical observations on 87 nosocomial and community-acquired cases. Am J Med Sci. 1984, 288 (1): 2-12. 10.1097/00000441-198407000-00001.CrossRefPubMed
19.
go back to reference Pedro-Botet ML, Sabria-Leal M, Haro M, et al: Nosocomial and community-acquired Legionella pneumonia: clinical comparative analysis. Eur Respir J. 1995, 8 (11): 1929-33. 10.1183/09031936.95.08111929.CrossRefPubMed Pedro-Botet ML, Sabria-Leal M, Haro M, et al: Nosocomial and community-acquired Legionella pneumonia: clinical comparative analysis. Eur Respir J. 1995, 8 (11): 1929-33. 10.1183/09031936.95.08111929.CrossRefPubMed
20.
go back to reference Benin AL, Benson RF, Besser RE: Trends in legionnaires disease, 1980-1998: declining mortality and new patterns of diagnosis. Clin Infect Dis. 2002, 35 (9): 1039-46. 10.1086/342903.CrossRefPubMed Benin AL, Benson RF, Besser RE: Trends in legionnaires disease, 1980-1998: declining mortality and new patterns of diagnosis. Clin Infect Dis. 2002, 35 (9): 1039-46. 10.1086/342903.CrossRefPubMed
21.
go back to reference Marston BJ, Lipman HB, Breiman RF: Surveillance for Legionnaires' disease. Risk factors for morbidity and mortality. Arch Intern Med. 1994, 154 (21): 2417-22. 10.1001/archinte.154.21.2417.CrossRefPubMed Marston BJ, Lipman HB, Breiman RF: Surveillance for Legionnaires' disease. Risk factors for morbidity and mortality. Arch Intern Med. 1994, 154 (21): 2417-22. 10.1001/archinte.154.21.2417.CrossRefPubMed
Metadata
Title
Clinical features and predictors of mortality in admitted patients with community- and hospital-acquired legionellosis: A Danish historical cohort study
Authors
Sanne Jespersen
Ole S Søgaard
Henrik C Schønheyder
Michael J Fine
Lars Østergaard
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2010
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-10-124

Other articles of this Issue 1/2010

BMC Infectious Diseases 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine